Login by entering your registration details below. Don't have an account yet? REGISTER HERE
Identifiez-vous en complétant les détails ci-dessous. Vous n’avez pas encore de compte? INSCRIVEZ-VOUS
Geben Sie unten ihre Registrierungsdaten ein um sich anzumelden - oder REGISTRIEREN Sie sich hier
Effettua il login inserendo i tuoi dati di registrazione qui sotto. Non hai ancora un account? REGISTRATI QUI
Introducir sus Datos de acceso – o REGISTRESE aquí.
SAN DIEGO, March 15, 2015 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for high- and intermediate-risk patients treated with the SAPIEN 3 transcatheter aortic valve demonstrated the lowest all-cause mortality rates of any of the PARTNER studies, as well as excellent clinical outcomes on the other components of the primary endpoint measures of stroke and paravalvular regurgitation.